Zobrazeno 1 - 4
of 4
pro vyhledávání: '"Noor M. Abdulkareem"'
Autor:
Mantasha Tabassum, Soumya G. Chikermane, Camille Johnson, Noor M. Abdulkareem, Elisabeth M. Wang, Michael L. Johnson, Meghana V. Trivedi
Publikováno v:
Cardio-Oncology, Vol 10, Iss 1, Pp 1-7 (2024)
Abstract Background Cardiovascular (CV) disease is a leading cause of death in breast cancer (BC) patients due to the increased age and treatments. While individual β-blockers have been investigated to manage CV complications, various β-blockers ha
Externí odkaz:
https://doaj.org/article/d68bdaebd5e34cefa3a68098abf8e26f
Autor:
Noor M Abdulkareem, Soumya G Chikermane, Suma Gopinathan, Michael L Johnson, Meghana V Trivedi
Publikováno v:
Cancer Research. 82:P2-11
Background: Breast cancer mortality has decreased along with advances in diagnosis and treatments. However, cardiovascular (CV) disease-related mortality is a growing concern in this population. Increased risk of CV diseases is primarily contributed
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::822618b1714cfa8485203f31e3c76bec
https://doi.org/10.1158/1538-7445.sabcs21-p2-11-09
https://doi.org/10.1158/1538-7445.sabcs21-p2-11-09
Autor:
Mantasha Tabassum, Alexis Ruiz, Noor M. Abdulkareem, Mothaffar F. Rimawi, George E. Miles, Meghana V. Trivedi
Publikováno v:
Cancer Research. 83:2136-2136
Introduction: Cyclin-dependent kinases 4/6 inhibitors (CDK4/6i) have emerged as a major advance in treating hormone receptor-positive/human epidermal growth factor receptor-2-negative breast cancer (HR+/HER2- BC), which accounts for over 60% of all b
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::66b8847909abf785218c551b1baf12a7
https://doi.org/10.1158/1538-7445.am2023-2136
https://doi.org/10.1158/1538-7445.am2023-2136
Publikováno v:
The FASEB Journal. 36
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::6696d02b4988bfd23abf3368e67dfe92
https://doi.org/10.1096/fasebj.2022.36.s1.r1981
https://doi.org/10.1096/fasebj.2022.36.s1.r1981